IceCure Medical Ltd. ICCM
- Market cap
- $6.5M
- P/E
- 0.0×
Follow ICCM
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 44.91 | 44.91 | 44.91 | 44.74 | 5.30 | 44.15 | 22.50 | 15.60 | 14.40 | 17.40 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 51.67 | 44.91 | 44.91 | 47.10 | 73.00 | 470.98 | 141.90 | 46.80 | 47.10 | 49.80 |
High Price
|
|||
| — | — | — | — | 60 | 64 | 46 | 78 | 66 | 69 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 1 | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 | 3 |
Revenue
|
|||
| 33.04% | 23.41% | 39.44% | 32.21% | 63.19% | 53.04% | 46.84% | 40.26% | 44.09% | 36.28% |
Gross Margin
|
|||
| (3) | (3) | (4) | (5) | (4) | (10) | (17) | (15) | (15) | (15) |
EBT
|
|||
| (522.82%) | (417.15%) | (329.70%) | (279.72%) | (96.43%) | (239.13%) | (550.34%) | (453.76%) | (465.45%) | (445.61%) |
EBT Margin
|
|||
| (3) | 0 | (4) | (5) | (4) | (10) | (17) | (15) | (15) | (15) |
Net Income
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| 0.12 | 0.11 | 0.09 | 3.59 | 6.78 | 4.35 | 2.50 | 2.12 | 1.94 | 1.60 |
Revenue/Sh
|
|||
| (0.61) | (0.46) | (0.30) | (10.03) | (6.54) | (10.51) | (13.81) | (9.61) | (9.01) | (7.21) |
Earnings/Sh
|
|||
| (0.59) | (0.41) | (0.26) | (4.38) | (6.47) | (13.26) | (11.59) | (8.26) | (7.42) | (6.88) |
Cash Flow/Sh
|
|||
| 0.00 | 0.00 | 0.00 | (0.23) | (0.39) | (0.56) | (0.72) | (0.32) | (0.04) | (0.02) |
Capex/Sh
|
|||
| (0.59) | (0.41) | (0.26) | (4.61) | (6.86) | (13.82) | (12.32) | (8.57) | (7.46) | (6.90) |
Free CF/Sh
|
|||
| 0.40 | (0.04) | 0.29 | 7.26 | 9.90 | 28.36 | 20.62 | 8.00 | 4.07 | 4.28 |
Book Value/Sh
|
|||
| 5 | 6 | 12 | 0 | 1 | 1 | 1 | 2 | 2 | 2 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 198.99 | 697.06 | 311.69 | 455.31 | 19.09 | 12.98 |
PS Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 187.39 | 196.69 | 106.19 | 61.97 | 130.53 | 7.44 | 3.88 |
PB Ratio
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 198.41 | 691.02 | 307.06 | 452.28 | 16.38 | 9.75 |
EV/Sales
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | (131.14) | (216.01) | (54.65) | (62.25) | (1.84) | (1.06) |
EV/FCF
|
|||
| (3) | (3) | (3) | (2) | (4) | (13) | (14) | (13) | (13) | (15) |
Op' Cash Flow
|
|||
| 0 | 0 | 0 | 0 | 0 | (1) | (1) | 0 | 0 | 0 |
Capex
|
|||
| (3) | (3) | (3) | (2) | (4) | (13) | (15) | (13) | (13) | (15) |
FCF
|
|||
| 3 | 0 | 4 | 3 | 6 | 26 | 24 | 10 | 5 | 8 |
Working Cap'
|
|||
| — | 1 | — | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Total Debt
|
|||
| (3) | (1) | (4) | (6) | (3) | (25) | (24) | (11) | (7) | (9) |
Net Debt
|
|||
| 2 | 0 | 3 | 3 | 6 | 27 | 25 | 12 | 7 | 9 |
Sh' Equity
|
|||
| (124.73%) | (173.60%) | (134.53%) | (72.51%) | (42.59%) | (46.54%) | (54.36%) | (62.89%) | (105.69%) | (113.79%) |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | (114.34%) | (300.57%) | (551.50%) | (659.11%) | 0.00% | (5,648.95%) |
ROIC
|
|||
| (354.30%) | (311.54%) | (227.23%) | (136.41%) | (83.45%) | (60.69%) | (64.83%) | (77.97%) | (160.70%) | (188.78%) |
ROE
|
|||
IceCure Medical Ltd. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NVNO enVVeno Medical Corporation | $6.3M | 0.0× | Compare |
| VNRX VolitionRX Limited | $6.9M | 0.0× | Compare |
| INBS Intelligent Bio Solutions Inc. | $5.7M | 0.0× | Compare |
| AMIX Autonomix Medical, Inc. | $7.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TBIO Telesis Bio Inc. | $5.3M | 0.0× | Compare |
| CODX Co-Diagnostics, Inc. | $8.3M | 0.0× | Compare |
| VVOS Vivos Therapeutics, Inc. | $4.9M | 0.0× | Compare |
| WOK WORK Medical Technology Group LTD | $8.9M | — | Compare |
IceCure Medical Ltd. (ICCM) key facts
- IceCure Medical Ltd. (ICCM) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- IceCure Medical Ltd.’s revenue for fiscal 2025 (year ended December 2025) was ILS 3.4 million, up 2.67% from fiscal 2024.
- As of September 25, 2026, ICCM traded at $1.73, a market capitalization of $6.5 million.
- Return on equity was −188.8% and debt-to-equity 0.00.
IceCure Medical Ltd. (ICCM) Latest News
11 Sep
IceCure Medical Ltd. obtained China NMPA approval for its ProSense Cryoablation System. NMPA approval enables commercial sales of ProSense across China, a major growth market.
10 Sep
IceCure Medical Ltd. (ICCM) receives regulatory approval to market ProSense® in China. Approval enables ProSense® sales across major Chinese market expanding revenue potential.
24 Aug
IceCure Medical Ltd. signed an exclusive distribution agreement for ProSense Cryoablation Systems in the Netherlands. Deal expands ProSense reach into the Netherlands market but covers only one small country.
20 Aug
West Cancer Center receives IRB approval to commence IceCure's ChoICE study for breast cancer cryoablation. IRB approval advances clinical testing of company's breast cancer cryoablation technology.
19 Aug
IceCure Medical Ltd (ICCM) reported 45% revenue growth in Q2 2026 earnings call, driven by US market developments. 45% revenue surge points to strong financial momentum and US expansion that can shift company trajectory and investor views.
IceCure Medical Ltd. held its Q2 2026 earnings call to review financial results, operational progress, and forward guidance. Quarterly earnings calls deliver financial updates and outlook that can shift near-term investor sentiment and trading activity.
13 Aug
IceCure Medical Ltd. highlights two new peer-reviewed publications supporting cryoablation for breast cancer treatment de-escalation. Peer-reviewed support for cryoablation boosts IceCure's technology credibility and potential adoption in breast cancer care.
12 Aug
IceCure Medical Ltd held Q2 2026 earnings call. Earnings updates moderately influence company financial outlook and investor views.
IceCure Medical Ltd. (ICCM) reported financial results for the first half of 2026 showing 45% year-over-year revenue growth. 45% revenue growth signals improved financial performance that may boost near-term market sentiment without fundamentally altering long-term trajectory.
6 Aug
IceCure Medical adds Adventist Health as a U.S. clinical site for its ChoICE post-marketing study on cryoablation treatment for low-risk breast cancer. Clinical site expansion advances study progress and supports potential treatment adoption.
29 Jul
SIO petitions NCCN to include cryoablation in breast cancer treatment guidelines citing IceCure's FDA-cleared ProSense®. NCCN guideline inclusion for ProSense® could drive broad clinical adoption and revenue growth.
27 Jul
IceCure Medical launches post-marketing ChoICE study for low-risk breast cancer treatment at first U.S. clinical site. ChoICE study initiation at first U.S. site advances breast cancer treatment development and U.S. positioning.
14 Jul
IceCure Medical expands its U.S. commercial team to meet surging demand for ProSense cryoablation. Team expansion signals rising product adoption and operational scaling with moderate effects on growth trajectory.
6 Jul
IceCure reports growing commercial adoption of ProSense cryoablation in Brazil after FDA clearance for breast cancer treatment. FDA clearance plus Brazil adoption signals major regulatory win and international revenue growth potential.
23 Jun
IceCure Medical highlights peer-reviewed article in leading surgery journal showing cryoablation superior to radiofrequency ablation for early-stage breast cancer treatment. Peer-reviewed validation of cryoablation advantages boosts company credibility and supports future adoption in breast cancer therapy.
17 Jun
IceCure Medical Ltd. (ICCM) shares surge 200% and head for the best session in nearly five years on heavy trading volume. 200% single-day rally signals major positive catalyst likely to shift near-term valuation and investor sentiment.
IceCure Medical reports 70% growth in active U.S. commercial install base for breast cancer cryoablation following FDA clearance. FDA clearance triggers 70% U.S. install base growth, strengthening commercial traction and market position.
IceCure Medical prices $5.5 million private placement at premium to market with single healthcare-focused institutional investor. Secures capital at premium terms to fund operations and development.
20 May
IceCure Medical Ltd (ICCM) reported robust revenue growth in its Q1 2026 earnings call. Robust revenue growth in Q1 2026 earnings signals stronger financial results that can lift stock performance and investor outlook.
19 May
IceCure's ProSense achieved nearly 90% recurrence-free rate in kidney cancer cryoablation with data presented at ECIO 2026. The company's first breast cryoablation master class was overbooked. Strong kidney cancer efficacy data plus overbooked breast training event point to rising clinical adoption and positive investor sentiment for ProSense.
15 May
IceCure Medical Ltd held its Q1 2026 earnings call covering quarterly financial results, operational updates, and forward outlook. Quarterly earnings call delivers financial metrics and strategy details with moderate influence on near-term performance and sentiment.
13 May
IceCure Medical Ltd. (ICCM) received a 180-day extension from Nasdaq to regain compliance with the minimum bid price listing requirement. Nasdaq extension prevents immediate delisting and supports short-term market presence but signals persistent stock price challenges.
12 May
IceCure Medical Ltd. (ICCM) released its Q1 2026 earnings call transcript, covering quarterly financial results, operational updates, and management's outlook. Q1 2026 earnings transcript reveals financial metrics, strategic developments, and guidance that could significantly sway investor sentiment and stock trajectory.
IceCure Medical Ltd. (ICCM) reported first quarter 2026 financial results, with ProSense® sales increasing substantially in the U.S. and North America. Substantial ProSense® sales growth in the U.S. and North America drives significant revenue momentum and enhances competitive positioning.
IceCure Medical Ltd. (ICCM) reported a Q1 net loss of $2.1 million, or $0.04 per share, compared to $1.8 million loss last year; revenue fell to $321,000 from $510,000, missing estimates. Q1 loss widened and revenue missed estimates, impacting financial performance and investor sentiment moderately.
5 May
IceCure Medical Ltd. (ICCM) showcased ProSense® Cryoablation at the American Society of Breast Surgeons 2026 Annual Meeting amid accelerating commercial momentum in the U.S. market. Showcasing at a premier breast surgeons' meeting underscores accelerating U.S. commercialization of ProSense®, likely enhancing competitive positioning and investor sentiment.
21 Apr
IceCure Medical Ltd. (ICCM) participates in the Society of Breast Imaging Symposium 2026 as U.S. ProSense® revenue rises over 30% in Q1 2026 compared to Q1 2025. Over 30% U.S. ProSense revenue growth in Q1 2026 signals strong commercial traction and positions ICCM for enhanced market performance.
26 Mar
IceCure Medical Ltd. (ICCM) announces pricing of $4.0 million registered direct offering and concurrent private placement. The $4.0 million capital raise via registered direct offering and private placement provides significant funding to support operations, clinical trials, and growth for the microcap biotech.
25 Mar
IceCure Medical Ltd. (ICCM) reports positive 5-year top-line results from ICESECRET kidney cancer cryoablation study: 89.4% and 83.9% recurrence-free rates. Positive long-term data from ICESECRET study validates IceCure's cryoablation for kidney cancer, likely accelerating regulatory approvals and market adoption.
20 Mar
IceCure Medical Ltd (ICCM) reported record Q4 2025 sales and strategic U.S. advancements in earnings call highlights. Record sales combined with strategic U.S. initiatives represent major growth drivers and market expansion for ICCM.